The best GLP-1 for you comes down to a few personal factors: how much weight you want to lose, how well you tolerate side effects, whether you prefer a pill or an injection, what you can afford, and your other health conditions. Tirzepatide (Zepbound, Mounjaro) tends to produce the most weight loss, while semaglutide (Wegovy, Ozempic) is well-established and sometimes costs less. Research shows these drugs work well across ages, races, and starting weights, so the decision is less about who you are and more about your goals and preferences. Here’s how to think it through.<\/p>\n
The size of your weight loss goal is a reasonable first filter. If you have a lot to lose or want the largest average result, tirzepatide leads among approved options, with trial averages around 20%. If your goal is more moderate, semaglutide (around 15%) may be plenty, especially if cost or availability points you there. Neither is a wrong choice; they’re different points on the same spectrum.<\/p>\n
Reassuringly, the drugs work broadly. In a systematic review and meta-analysis published in JAMA Internal Medicine<\/a> in 2026, GLP-1 medications produced consistent weight loss across age, race, ethnicity, and starting BMI, with women losing a somewhat larger percentage than men. In practice, that means your demographics shouldn’t steer the choice much. Your priorities should.<\/p>\n TrimRx prescribes compounded semaglutide and compounded tirzepatide along with the brand injectables, so both leading options are available after a provider review. A few decision points are worth spelling out.<\/p>\n Tolerability is manageable for most people regardless of which you pick, and how you start (a low dose, increased slowly) matters more than the drug itself. Route is a real preference: the strongest options are weekly injections with a small needle, while oral GLP-1s exist for the needle-averse but are available through their manufacturers rather than TrimRx and tend to produce less weight loss. Cost varies by drug and channel, and because TrimRx is cash-pay, you won’t be dealing with insurance approvals. Finally, your health conditions can tip the scales: someone with obesity and sleep apnea has a clear reason to consider tirzepatide, since it’s the only drug approved for that use.<\/p>\n Consider a hypothetical patient deciding between the two. She has about 40 pounds to lose, a limited budget, and no needle phobia. Semaglutide could be a sensible, cost-conscious starting point, with the option to switch to tirzepatide later if her results stall. A different patient with 90 pounds to lose and sleep apnea might reasonably start with tirzepatide from the outset. You can read more about the service on the TrimRx homepage<\/a>.<\/p>\n Choosing a GLP-1 isn’t a permanent commitment. Many people start with one drug and switch based on results and tolerance, which a provider can manage with appropriate dose adjustments. Treating the first choice as a starting point rather than a final verdict takes some pressure off the decision.<\/p>\n Tirzepatide produces more weight loss on average, while semaglutide is well-established and may cost less. If your goal is large or you have sleep apnea, tirzepatide has an edge; if cost matters most, semaglutide is a strong, proven option.<\/p>\n Sometimes. Tirzepatide is the only drug approved for moderate-to-severe sleep apnea with obesity, and both drugs help with conditions like insulin resistance and high blood pressure. Your other conditions can reasonably guide the choice.<\/p>\n Yes. Switching is common and manageable with a provider’s guidance, including a proper dose adjustment. Many people change medications based on results or tolerance.<\/p>\nWeigh the Practical Factors<\/h3>\n
\n\n
\n \nFactor<\/th>\n Points toward<\/th>\n Why<\/th>\n<\/tr>\n<\/thead>\n \n Largest weight loss<\/td>\n Tirzepatide<\/td>\n Highest average results among approved drugs<\/td>\n<\/tr>\n \n Lower cost<\/td>\n Semaglutide or self-pay options<\/td>\n Often priced below tirzepatide<\/td>\n<\/tr>\n \n Sensitive stomach<\/td>\n Slow titration, either drug<\/td>\n Tirzepatide had slightly fewer GI discontinuations in trials<\/td>\n<\/tr>\n \n Prefer a pill<\/td>\n Oral options (via manufacturer)<\/td>\n Needle-free, though generally less potent<\/td>\n<\/tr>\n \n Sleep apnea with obesity<\/td>\n Tirzepatide (Zepbound)<\/td>\n The only drug approved for moderate-to-severe OSA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n You Can Change Course<\/h3>\n
Frequently Asked Questions<\/h3>\n
Should I choose semaglutide or tirzepatide?<\/h4>\n
Does it matter which GLP-1 I pick if I have a specific health condition?<\/h4>\n
Can I switch GLP-1s if the first one doesn’t work well?<\/h4>\n